These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36800065)

  • 41. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible
    Burdet C; Loubet P; Le Moing V; Vindrios W; Esposito-Farèse M; Linard M; Ferry T; Massias L; Tattevin P; Wolff M; Vandenesch F; Grall N; Quintin C; Mentré F; Duval X; Lescure FX;
    BMJ Open; 2018 Sep; 8(8):e023151. PubMed ID: 30173161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?
    Lee S; Choe PG; Song KH; Park SW; Kim HB; Kim NJ; Kim EC; Park WB; Oh MD
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5122-6. PubMed ID: 21825299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Ulloa ER; Singh KV; Geriak M; Haddad F; Murray BE; Nizet V; Sakoulas G
    Clin Infect Dis; 2020 Sep; 71(6):1413-1418. PubMed ID: 31773134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effectiveness of empirical antibiotic treatments in methicillin-susceptible Staphylococcus aureus infective endocarditis: A post hoc analysis of a prospective French cohort study.
    Lecomte R; Deschanvres C; Bourreau A; Ruffier d'Epenoux L; Le Turnier P; Gaborit B; Chauveau M; Michel M; Le Tourneau T; Bémer P; Corvec S; Boutoille D
    Int J Infect Dis; 2024 May; 142():106989. PubMed ID: 38428479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.
    Stryjewski ME; Szczech LA; Benjamin DK; Inrig JK; Kanafani ZA; Engemann JJ; Chu VH; Joyce MJ; Reller LB; Corey GR; Fowler VG
    Clin Infect Dis; 2007 Jan; 44(2):190-6. PubMed ID: 17173215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of Outpatient Parenteral Antimicrobial Therapy With Ceftriaxone for Methicillin-Susceptible
    Hamad Y; Connor L; Bailey TC; George IA
    Open Forum Infect Dis; 2020 Sep; 7(9):ofaa341. PubMed ID: 32908944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals.
    McDanel JS; Perencevich EN; Diekema DJ; Herwaldt LA; Smith TC; Chrischilles EA; Dawson JD; Jiang L; Goto M; Schweizer ML
    Clin Infect Dis; 2015 Aug; 61(3):361-7. PubMed ID: 25900170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antistaphylococcal penicillins versus cephalosporins for definitive treatment of meticillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.
    Vardakas KZ; Apiranthiti KN; Falagas ME
    Int J Antimicrob Agents; 2014 Dec; 44(6):486-92. PubMed ID: 25311850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of an assay that enables rapid determination of Staphylococcus species and their drug susceptibility on the treatment of patients with positive blood culture results.
    Parta M; Goebel M; Thomas J; Matloobi M; Stager C; Musher DM
    Infect Control Hosp Epidemiol; 2010 Oct; 31(10):1043-8. PubMed ID: 20731594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.
    Weis S; Kesselmeier M; Davis JS; Morris AM; Lee S; Scherag A; Hagel S; Pletz MW
    Clin Microbiol Infect; 2019 Jul; 25(7):818-827. PubMed ID: 30928559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis.
    Lee BJ; Wang SK; Constantino-Corpuz JK; Apolinario K; Nadler B; McDanel JS; Scheetz MH; Rhodes NJ
    Int J Antimicrob Agents; 2019 Mar; 53(3):225-233. PubMed ID: 30476572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?
    Paul M; Zemer-Wassercug N; Talker O; Lishtzinsky Y; Lev B; Samra Z; Leibovici L; Bishara J
    Clin Microbiol Infect; 2011 Oct; 17(10):1581-6. PubMed ID: 21073629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
    Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
    JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Flucloxacillin and cefazolin for treatment of Staphylococcus aureus bloodstream infection.
    Schmidt-Hellerau K; Breuninger M; Kessel J; Vehreschild MJGT; Paul G; Reusch J; Jung N; Hellmich M; Fätkenheuer G
    Infection; 2024 Jun; 52(3):1159-1163. PubMed ID: 38296936
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Penicillin versus anti-staphylococcal beta-lactams for penicillin-susceptible Staphylococcus aureus blood stream infections: a retrospective cohort study.
    Reynolds G; Crawford S; Cuenca J; Ghosh N; Newton P
    Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):147-151. PubMed ID: 34432165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retrospective Analysis of Adverse Drug Events Between Nafcillin Versus Cefazolin for Treatment of Methicillin-Susceptible
    Chan L; Chan-Tompkins NH; Como J; Guarascio AJ
    Ann Pharmacother; 2020 Jul; 54(7):662-668. PubMed ID: 31888347
    [No Abstract]   [Full Text] [Related]  

  • 57. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.
    Herrera-Hidalgo L; Muñoz P; Álvarez-Uría A; Alonso-Menchén D; Luque-Marquez R; Gutiérrez-Carretero E; Fariñas MDC; Miró JM; Goenaga MA; López-Cortés LE; Angulo-Lara B; Boix-Palop L; de Alarcón A;
    Int J Infect Dis; 2023 Dec; 137():134-143. PubMed ID: 37926195
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation.
    Antosz K; Battle S; Chang J; Scheetz MH; Al-Hasan M; Bookstaver PB
    Pharmacotherapy; 2023 Jan; 43(1):85-95. PubMed ID: 36521869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.
    Chan KE; Warren HS; Thadhani RI; Steele DJ; Hymes JL; Maddux FW; Hakim RM
    J Am Soc Nephrol; 2012 Sep; 23(9):1551-9. PubMed ID: 22904350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.
    McConeghy KW; Bleasdale SC; Rodvold KA
    Clin Infect Dis; 2013 Dec; 57(12):1760-5. PubMed ID: 23985343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.